Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure.

Diagn Microbiol Infect Dis. 1998 Nov;32(3):211-6. Unique Identifier : AIDSLINE MED/99100576
Milan EP; Burattini MN; Kallas EG; Fischmann O; Costa PR; Colombo AL; Division of Infectious Diseases, Escola Paulista de Medicina,; Universidade Federal de Sao Paulo, Brazil.

Abstract: This is a prospective study designed to investigate species distribution and azole susceptibility profile among Candida spp. isolated from the oral cavities of AIDS patients. One hundred thirty-two AIDS patients sequentially admitted at a teaching tertiary care hospital were enrolled in this study. Samples were obtained by swabbing the oral cavities of the patients. Yeast isolates were identified by classical methods and the antifungal susceptibility profile was further determined according to the NCCLS microbroth assay. Among all patients with prescriptions of systemic antifungal drugs, ketoconazole had been elected to treat 56% of patients. We found 82% of oral yeast carriage, 22% of them harboring non-albicans species. Overall rates of susceptibility dose dependent/resistance to azoles was 16% for itraconazole, 13% for ketoconazole, and 10% for fluconazole with a high agreement rate among the susceptibility profiles of all isolates tested against the triazoles.
Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Aged Antifungal Agents/*PHARMACOLOGY/THERAPEUTIC USE Azoles/*PHARMACOLOGY/THERAPEUTIC USE Brazil/EPIDEMIOLOGY Candida albicans/*DRUG EFFECTS Candidiasis, Oral/*DRUG THERAPY/MICROBIOLOGY Drug Resistance, Microbial Female Fluconazole/PHARMACOLOGY/THERAPEUTIC USE Human Itraconazole/PHARMACOLOGY/THERAPEUTIC USE Ketoconazole/PHARMACOLOGY/THERAPEUTIC USE Male Microbial Sensitivity Tests Middle Age Mouth Mucosa/MICROBIOLOGY Mycology/METHODS Prevalence Prospective Studies Statistics, NonparametricKWDjournalarticleacquiredimmunodeficiencysyndrome/KWDcomplicationsadultagedantifungalagents/KWDpharmacology/therapeuticuseazoles/KWDpharmacology/therapeuticusebrazil/epidemiologycandidaalbicans/KWDdrugeffectscandidiasis,oral/
990630
A9960941

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .